{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-037234","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-09-21T20:05:54+00:00","discovered_at":"2026-09-21T20:07:41.359663+00:00","generated_at":"2026-09-21T20:07:51.120755+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"low","headline":"PDS Biotech updates corporate presentation deck; no new trial or financial data disclosed","bullets":["On September 21, 2026, PDS Biotechnology (NASDAQ: PDSB) posted an updated corporate presentation.","Deck titled 'Overview of PDS Biotech Drug Development Programs (Oncology)' — oncology immunotherapy focus.","Exhibit text provided contains only the cover slide; no dosing, efficacy, or financial figures included.","Filing signed by Frank Bedu-Addo, Ph.D., President and CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-037234","json":"https://secwatch.observer/filing/0001140361-26-037234.json","markdown":"https://secwatch.observer/filing/0001140361-26-037234.md","text":"https://secwatch.observer/filing/0001140361-26-037234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/0001140361-26-037234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/ef20082538_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T20:07:51.120755+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}